Recruiting
Phase 3

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Sponsor:

Taiho Oncology, Inc.

Code:

NCT05973773

Conditions

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TAS6417

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information